Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant OxMdG before short-course preoperative radiotherapy for high-risk operable rectal cancer
2010-023083-40Phase 2Terminated
- Sponsor
- Cardiff University
- Start
- Mar 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and capecitabine in rectal adenocarcinoma, sponsored by Cardiff University. Primary endpoint: Feasibility of treatment sequence. Started Mar 2012; status: terminated.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2010-023083-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023083-40.